National Estimates of Healthcare Costs Associated With Multidrug-Resistant Bacterial Infections Among Hospitalized Patients in the United States
04 March 2021
Treating patients with infections due to multidrug-resistant pathogens often requires substantial healthcare resources. The purpose of this study was to report estimates of the healthcare costs associated with infections due to multidrug-resistant bacteria in the United States (US).
We found that antimicrobial-resistant infections led to substantial healthcare costs.
Further reading: Clinical Infectious Diseases
Author(s): Richard E Nelson, Kelly M Hatfield, Hannah Wolford, Matthew H Samore, R Douglas Scott, II, Sujan C Reddy, Babatunde Olubajo, Prabasaj Paul, John A Jernigan, James Baggs
Effective Surveillance
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Evotec |
 |
JSS University |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Technology Database
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.
